SAB Biotherapeutics (NASDAQ:SABS) Releases Earnings Results, Misses Expectations By $0.05 EPS

SAB Biotherapeutics (NASDAQ:SABS) issued its quarterly earnings data on Wednesday. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05), Zacks reports. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ:SABS traded up $0.24 on Friday, hitting $3.51. 86,453 shares of the company’s stock were exchanged, compared to its average volume of 29,686. The firm’s 50-day moving average is $2.90 and its 200 day moving average is $3.01. SAB Biotherapeutics has a 1-year low of $2.16 and a 1-year high of $9.72. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.07.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SABS. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Craig Hallum began coverage on SAB Biotherapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $11.00 target price for the company. Finally, Oppenheimer reissued an “outperform” rating and set a $12.00 target price on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of “Buy” and an average price target of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.